Synthesis, Conjugation, and Labeling of Multifunctional pRNA Nanoparticles for Specific Delivery of siRNA, Drugs, and Other Therapeutics to Target Cells

  • Peixuan Guo
  • Yi Shu
  • Daniel Binzel
  • Mathieu CinierEmail author
Part of the Methods in Molecular Biology book series (MIMB, volume 928)


RNA is unique in nanoscale fabrication due to its amazing diversity of function and structure. RNA nanoparticles can be fabricated with a level of simplicity characteristic of DNA while possessing versatile tertiary structure and catalytic function similar to that of proteins. A large variety of single stranded loops are suitable for inter- and intramolecular interactions, serving as mounting dovetails in self-assembly without the need for external linking dowels. Novel properties of RNA nanoparticles have been explored for treatment and detection of diseases and various other realms. The higher thermodynamic stability, holding of noncanonical base pairing, stronger folding due to base stacking properties, and distinctive in vivo attributes make RNA unique in comparison to DNA. Indeed, the potential application of RNA nanotechnology in therapeutics is an exciting area of research.

The use of RNAi in biomedical research has opened up new possibilities to silence or regulate the biological function of individual genes. Small interfering RNA (siRNA) has been extensively explored to genetically manipulate the expression in vitro and in vivo of particular genes identified to play a key role in cancerous or viral diseases. However, the efficient silencing of the desired gene depends upon efficient delivery of siRNA to targeted cells, as well as in vivo stability. In this chapter, we use the bacteriophage phi29 motor pRNA-derived nanocarrier as a polyvalent targeted delivery system, introduce the potential of RNA-based therapeutics using nanobiotechnology or nanotechnology methods with the fabrication and modification of pRNA nanoparticles, and highlight its potential to become a valuable research tool and viable clinical approach for gene therapy.

Key words

Bacteriophage phi29 Nanomotors RNA nanotechnology Nanobiotechnology Bottom-up assembly pRNA nanoparticle RNAi Cell-type specific delivery Viral DNA packaging motor Viral assembly 



This work was supported by NIH grants EB003730, GM059944, and CA151648. We also thank Dr. Randall Reif for helpful discussion and reading of the manuscript.


  1. 1.
    Niemeyer CM (2002) The developments of semisynthetic DNA-protein conjugates. Trends Biotechnol 20:395–401PubMedCrossRefGoogle Scholar
  2. 2.
    Schmidt OG, Eberl K (2001) Nanotechnology. Thin solid films roll up into nanotubes. Nature 410:168PubMedCrossRefGoogle Scholar
  3. 3.
    Guo P (2005) RNA nanotechnology: engineering, assembly and applications in detection, gene delivery and therapy. J Nanosci Nanotechnol 5:1964–1982PubMedCrossRefGoogle Scholar
  4. 4.
    Guo P, Zhang C, Chen C, Trottier M, Garver K (1998) Inter-RNA interaction of phage phi29 pRNA to form a hexameric complex for viral DNA transportation. Mol Cell 2:149–155PubMedCrossRefGoogle Scholar
  5. 5.
    Zhang F, Lemieux S, Wu X, St.-Arnaud S, McMurray CT, Major F, Anderson D (1998) Function of hexameric RNA in packaging of bacteriophage phi29 DNA in vitro. Mol Cell 2:141–147PubMedCrossRefGoogle Scholar
  6. 6.
    Shu D, Moll WD, Deng Z, Mao C, Guo P (2004) Bottom-up assembly of RNA arrays and superstructures as potential parts in nanotechnology. Nano Lett 4:1717–1723PubMedCrossRefGoogle Scholar
  7. 7.
    Jaeger L, Leontis NB (2000) Tecto-RNA: one dimensional self-assembly through tertiary interactions. Angew Chem Int Ed Engl 39:2521–2524PubMedCrossRefGoogle Scholar
  8. 8.
    Hansma HG, Oroudjev E, Baudrey S, Jaeger L (2003) TectoRNA and ‘kissing-loop’ RNA: atomic force microscopy of self-assembling RNA structures. J Microsc 212:273–279PubMedCrossRefGoogle Scholar
  9. 9.
    Cech TR, Zaug AJ, Grabowski PJ (1981) In vitro splicing of the ribosomal RNA precursor of Tetrahymena: involvement of a guanosine nucleotide in the excision of the intervening sequence. Cell 27:487–496PubMedCrossRefGoogle Scholar
  10. 10.
    Kruger K, Grabowski PJ, Zaug AJ, Sands J, Gottschling DE, Cech TR (1982) Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena. Cell 31:147–157PubMedCrossRefGoogle Scholar
  11. 11.
    Cech TR, Tanner NK, Tinoco I, Weir BR, Zuker M, Perlman PS (1983) Secondary structure of the tetrahymena ribosomal RNA intervening sequence: structural homology with fungal mitochondrial intervening sequences. Proc Natl Acad Sci USA 80:3903–3907PubMedCrossRefGoogle Scholar
  12. 12.
    Zaug AJ, Grabowski PJ, Cech TR (1983) Autocatalytic cyclization of an excised intervening sequence RNA is a cleavage-ligation reaction. Nature 301:578–583PubMedCrossRefGoogle Scholar
  13. 13.
    Hoeprich S, Zhou Q, Guo S, Qi G, Wang Y, Guo P (2003) Bacterial virus phi29 pRNA as a hammerhead ribozyme escort to destroy hepatitis B virus. Gene Ther 10:1258–1267PubMedCrossRefGoogle Scholar
  14. 14.
    Liu H, Guo S, Roll R, Li J, Diao Z, Shao N, Riley MR, Cole AM, Robinson JP, Snead NM, Shen G, Guo P (2007) Phi29 pRNA vector for efficient escort of hammerhead ribozyme targeting survivin in multiple cancer cells. Cancer Biol Ther 6:697–704PubMedCrossRefGoogle Scholar
  15. 15.
    Guo P (2010) The emerging field of RNA nanotechnology. Nat Nanotechnol 5:833–842PubMedCrossRefGoogle Scholar
  16. 16.
    Bouvet P (2001) Determination of nucleic acid recognition sequences by SELEX. Methods Mol Biol 148:603–610PubMedGoogle Scholar
  17. 17.
    Ciesiolka J, Gorski J, Yarus M (1995) Selection of an RNA domain that binds Zn2+. RNA 1:538–550PubMedGoogle Scholar
  18. 18.
    Clark S, Remcho V (2002) Aptamers as analytical reagents. Electrophoresis 23:1335–1340PubMedCrossRefGoogle Scholar
  19. 19.
    Kraus E, James W, Barclay AN (1998) Cutting edge: novel RNA ligands able to bind CD4 antigen and inhibit CD4+ T lymphocyte function. J Immunol 160:5209–5212PubMedGoogle Scholar
  20. 20.
    Shu D, Guo P (2003) A viral RNA that binds ATP and contains an motif similar to an ATP-binding aptamer from SELEX. J Biol Chem 278:7119–7125PubMedCrossRefGoogle Scholar
  21. 21.
    Gold L (1995) The SELEX process: a surprising source of therapeutic and diagnostic compounds. Harvey Lect 91:47–57PubMedGoogle Scholar
  22. 22.
    Ellington AD, Szostak JW (1990) In vitro selection of RNA molecules that bind specific ligands. Nature 346:818–822PubMedCrossRefGoogle Scholar
  23. 23.
    Tuerk C, Gold L (1990) Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA ploymerase. Science 249:505–510PubMedCrossRefGoogle Scholar
  24. 24.
    Khaled A, Guo S, Li F, Guo P (2005) Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology. Nano Lett 5:1797–1808PubMedCrossRefGoogle Scholar
  25. 25.
    McNamara JO, Andrechek ER, Wang Y, Viles KD, Rempel RE, Gilboa E, Sullenger BA, Giangrande PH (2006) Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 24:1005–1015PubMedCrossRefGoogle Scholar
  26. 26.
    Dassie JP, Liu XY, Thomas GS, Whitaker RM, Thiel KW, Stockdale KR, Meyerholz DK, McCaffrey AP, McNamara JO, Giangrande PH (2009) Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 27:839–849PubMedCrossRefGoogle Scholar
  27. 27.
    Zhou J, Swiderski P, Li H, Zhang J, Neff CP, Akkina R, Rossi JJ (2009) Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res 37:3094–3109PubMedCrossRefGoogle Scholar
  28. 28.
    Zhou J, Li H, Zaia J, Rossi JJ (2008) Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol Ther 16:1481–1489PubMedCrossRefGoogle Scholar
  29. 29.
    Cerchia L, de Franciscis V (2010) Targeting cancer cells with nucleic acid aptamers. Trends Biotechnol 28:517–525PubMedCrossRefGoogle Scholar
  30. 30.
    Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806–811PubMedCrossRefGoogle Scholar
  31. 31.
    Ghildiyal M, Zamore PD (2009) Small silencing RNAs: an expanding universe. Nat Rev Genet 10:94–108PubMedCrossRefGoogle Scholar
  32. 32.
    Guo P, Coban O, Snead NM, Trebley J, Hoeprich S, Guo S, Shu Y (2010) Engineering RNA for targeted siRNA delivery and medical application. Adv Drug Deliv Rev 62:650–666PubMedCrossRefGoogle Scholar
  33. 33.
    Li H, Li WX, Ding SW (2002) Induction and suppression of RNA silencing by an animal virus. Science 296:1319–1321PubMedCrossRefGoogle Scholar
  34. 34.
    Brummelkamp TR, Bernards R, Agami R (2002) A system for stable expression of short interfering RNAs in mammalian cells. Science 296:550–553PubMedCrossRefGoogle Scholar
  35. 35.
    Jacque JM, Triques K, Stevenson M (2002) Modulation of HIV-1 replication by RNA interference. Nature 418:435–438PubMedCrossRefGoogle Scholar
  36. 36.
    Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP, Rubin MA, Chinnaiyan AM (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624–629PubMedCrossRefGoogle Scholar
  37. 37.
    Carmichael GG (2002) Medicine: silencing viruses with RNA. Nature 418:379–380PubMedCrossRefGoogle Scholar
  38. 38.
    Sarver NA, Cantin EM, Chang PS, Zaia JA, Ladne PA, Stephens DA, Rossi JJ (1990) Ribozymes as potential anti-HIV-1 therapeutic agents. Science 247:1222–1225PubMedCrossRefGoogle Scholar
  39. 39.
    Chowrira BM, Berzal-Herranz A, Burke JM (1991) Novel guanosine requirement for catalysis by the hairpin ribozyme. Nature 354:320–322PubMedCrossRefGoogle Scholar
  40. 40.
    Forster AC, Symons RH (1987) Self-cleavage of virusoid RNA is performed by the proposed 55- nucleotide active site. Cell 50:9–16PubMedCrossRefGoogle Scholar
  41. 41.
    Nava Sarver N, Cantin EM, Chang PS, Zaia JA, Ladne PA, Stephens DA, Rossi JJ (1990) Ribozymes as potential anti-HIV-1 therapeutic agents. Science 24:1222–1225CrossRefGoogle Scholar
  42. 42.
    Guo S, Huang F, Guo P (2006) Construction of folate-conjugated pRNA of bacteriophage phi29 DNA packaging motor for delivery of chimeric siRNA to nasopharyngeal carcinoma cells. Gene Ther 13:814–820PubMedCrossRefGoogle Scholar
  43. 43.
    Coleman J, Hirashima A, Inocuchi Y, Green PJ, Inouye M (1985) A novel immune system against bacteriophage infection using complementary RNA (micRNA). Nature 315:601–603PubMedCrossRefGoogle Scholar
  44. 44.
    Knecht DA, Loomis WF (1987) Antisense RNA inactivation of myosin heavy chain gene expression in Dictyostelium discoideum. Science 236:1081–1086PubMedCrossRefGoogle Scholar
  45. 45.
    Liu J, Guo S, Cinier M, Shlyakhtenko L, Shu Y, Chen C, Shen G, Guo P (2010) Fabrication of stable and RNase—resistant RNA nanoparticles active in gearing the nanomotors for viral DNA packaging. ACS Nano 5:237–246PubMedCrossRefGoogle Scholar
  46. 46.
    Shu Y, Cinier M, Shu D, Guo P (2011) Assembly of multifunctional phi29 pRNA nanoparticles for specific delivery of siRNA and other therapeutics to targeted cells. Methods 54(2):204–214PubMedCrossRefGoogle Scholar
  47. 47.
    Abdelmawla S, Guo S, Zhang L, Pulukuri S, Patankar P, Conley P, Trebley J, Guo P, Li QX (2011) Pharmacological characterization of chemically synthesized monomeric pRNA nanoparticles for systemic delivery. Mol Ther 19(7):1312–1322PubMedCrossRefGoogle Scholar
  48. 48.
    Shu Y, Cinier M, Fox SR, Ben-Johnathan N, Guo P (2011) Assembly of therapeutic pRNA-siRNA nanoparticles using bipartite approach. Mol Ther 19(7):1304PubMedCrossRefGoogle Scholar
  49. 49.
    Guo P, Erickson S, Anderson D (1987) A small viral RNA is required for in vitro packaging of bacteriophage phi29 DNA. Science 236:690–694PubMedCrossRefGoogle Scholar
  50. 50.
    Shu D, Zhang H, Jin J, Guo P (2007) Counting of six pRNAs of phi29 DNA-packaging motor with customized single molecule dual-view system. EMBO J 26:527–537PubMedCrossRefGoogle Scholar
  51. 51.
    Chen C, Zhang C, Guo P (1999) Sequence requirement for hand-in-hand interaction in formation of pRNA dimers and hexamers to gear phi29 DNA translocation motor. RNA 5:805–818PubMedCrossRefGoogle Scholar
  52. 52.
    Guo S, Tschammer N, Mohammed S, Guo P (2005) Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA. Hum Gene Ther 16:1097–1109PubMedCrossRefGoogle Scholar
  53. 53.
    Glotzer SC (2004) Materials science. Some assembly required. Science 306:419–420PubMedCrossRefGoogle Scholar
  54. 54.
    Gates BD, Xu Q, Stewart M, Ryan D, Willson CG, Whitesides GM (2005) New approaches to nanofabrication: molding, printing, and other techniques. Chem Rev 105:1171–1196PubMedCrossRefGoogle Scholar
  55. 55.
    Tarapore P, Shu Y, Guo P, Ho SM (2010) Application of Phi29 motor pRNA for targeted therapeutic delivery of siRNA silencing metallothionein-IIA and survivin in ovarian cancers. Mol Ther 19:386–394PubMedCrossRefGoogle Scholar
  56. 56.
    Zhang HM, Su Y, Guo S, Yuan J, Lim T, Liu J, Guo P, Yang D (2009) Targeted delivery of anti-coxsackievirus siRNAs using ligand-conjugated packaging RNAs. Antiviral Res 83:307–316PubMedCrossRefGoogle Scholar
  57. 57.
    Shu Y, Shu D, Diao Z, Shen G, Guo P (2009) Fabrication of polyvalent therapeutic RNA nanoparticles for specific delivery of siRNA, ribozyme and drugs to targeted cells for cancer therapy. IEEE/NIH Life Science Systems and Applications Workshop, pp 9–12Google Scholar
  58. 58.
    Rusckowski M, Qu T, Roskey A, Agrawal S (2000) Biodistribution and metabolism of a mixed backbone oligonucleotide (GEM 231) following single and multiple dose administration in mice. Antisense Nucleic Acid Drug Dev 10:333–345PubMedCrossRefGoogle Scholar
  59. 59.
    Kawasaki AM, Casper MD, Freier SM, Lesnik EA, Zounes MC, Cummins LL, Gonzalez C, Cook PD (1993) Uniformly modified 2′-deoxy-2′-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets. J Med Chem 36:831–841PubMedCrossRefGoogle Scholar
  60. 60.
    Pieken WA, Olsen DB, Benseler F, Aurup H, Eckstein F (1991) Kinetic characterization of ribonuclease-resistant 2′-modified hammerhead ribozymes. Science 253:314–317PubMedCrossRefGoogle Scholar
  61. 61.
    Jaeger L, Verzemnieks EJ, Geary C (2009) The UA_handle: a versatile submotif in stable RNA architectures. Nucleic Acids Res 37:215–230PubMedCrossRefGoogle Scholar
  62. 62.
    Huang Y, Eckstein F, Padilla R, Sousa R (1997) Mechanism of ribose 2′-group discrimination by an RNA polymerase. Biochemistry 36:8231–8242PubMedCrossRefGoogle Scholar
  63. 63.
    Padilla R, Sousa R (1999) Efficient synthesis of nucleic acids heavily modified with non-canonical ribose 2′-groups using a mutantT7 RNA polymerase (RNAP). Nucleic Acids Res 27:1561–1563PubMedCrossRefGoogle Scholar
  64. 64.
    Sousa R, Padilla R (1995) A mutant T7 RNA polymerase as a DNA polymerase. EMBO J 14:4609–4621PubMedGoogle Scholar
  65. 65.
    Padilla R, Sousa R (2002) A Y639F/H784A T7 RNA polymerase double mutant displays superior properties for synthesizing RNAs with non-canonical NTPs. Nucleic Acids Res 30:e138PubMedCrossRefGoogle Scholar
  66. 66.
    Braasch DA, Jensen S, Liu Y, Kaur K, Arar K, White MA, Corey DR (2003) RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 42:7967–7975PubMedCrossRefGoogle Scholar
  67. 67.
    Harborth J, Elbashir SM, Vandenburgh K, Manninga H, Scaringe SA, Weber K, Tuschl T (2003) Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev 13:83–105PubMedCrossRefGoogle Scholar
  68. 68.
    Elmen J, Thonberg H, Ljungberg K, Frieden M, Westergaard M, Xu Y, Wahren B, Liang Z, Orum H, Koch T, Wahlestedt C (2005) Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res 33:439–447PubMedCrossRefGoogle Scholar
  69. 69.
    Layzer JM, McCaffrey AP, Tanner AK, Huang Z, Kay MA, Sullenger BA (2004) In vivo activity of nuclease-resistant siRNAs. RNA 10:766–771PubMedCrossRefGoogle Scholar
  70. 70.
    Huang F, Wang G, Coleman T, Li N (2003) Synthesis of adenosine derivatives as transcription initiators and preparation of 5′ fluorescein- and biotin-labeled RNA through one-step in vitro transcription. RNA 9:1562–1570PubMedCrossRefGoogle Scholar
  71. 71.
    Li N, Yu C, Huang F (2005) Novel cyanine-AMP conjugates for efficient 5′ RNA fluorescent labeling by one-step transcription and replacement of [gamma-32P]ATP in RNA structural investigation. Nucleic Acids Res 33:e37PubMedCrossRefGoogle Scholar
  72. 72.
    Huang F, He J, Zhang Y, Guo Y (2008) Synthesis of biotin-AMP conjugate for 5′ biotin labeling of RNA through one-step in vitro transcription. Nat Protoc 3:1848–1861PubMedCrossRefGoogle Scholar
  73. 73.
    Shu D, Zhang H, Petrenko R, Meller J, Guo P (2010) Dual-channel single-molecule fluorescence resonance energy transfer to establish distance parameters for RNA nanoparticles. ACS Nano 4:6843–6853PubMedCrossRefGoogle Scholar
  74. 74.
    Zhang CL, Trottier M, Guo PX (1995) Circularly permuted viral pRNA active and specific in the packaging of bacteriophage f29 DNA. Virology 207:442–451PubMedCrossRefGoogle Scholar
  75. 75.
    Zhang CL, Lee C-S, Guo P (1994) The proximate 5′ and 3′ ends of the 120-base viral RNA (pRNA) are crucial for the packaging of bacteriophage f29 DNA. Virology 201:77–85PubMedCrossRefGoogle Scholar
  76. 76.
    Zhang L, Sun L, Cui Z, Gottlieb RL, Zhang B (2001) 5′-sulfhydryl-modified RNA: initiator synthesis, in vitro transcription, and enzymatic incorporation. Bioconjug Chem 12:939–948PubMedCrossRefGoogle Scholar
  77. 77.
    Milligan JF, Groebe DR, Witherell GW, Uhlenbeck OC (1987) Oligoribonucleotide synthesis using T7 RNA polymerase and synthetic DNA templates. Nucleic Acids Res 15:8783–8798PubMedCrossRefGoogle Scholar
  78. 78.
    Bruce AG, Uhlenbeck OC (1978) Reactions at the termini of tRNA with T4 RNA ligase. Nucleic Acids Res 5:3665–3677PubMedCrossRefGoogle Scholar
  79. 79.
    Garver K, Guo P (2000) Mapping the inter-RNA interaction of phage phi29 by site-specific photoaffinity crosslinking. J Biol Chem 275:2817–2824PubMedCrossRefGoogle Scholar
  80. 80.
    Huang F (2003) Efficient incorporation of CoA, NAD and FAD into RNA by in vitro transcription. Nucleic Acids Res 31:e8PubMedCrossRefGoogle Scholar
  81. 81.
    Pan T, Gutell RR, Uhlenbeck OC (1991) Folding of circularly permuted transfer RNAs. Science 254:1361–1364PubMedCrossRefGoogle Scholar
  82. 82.
    Nolan JM, Burke DH, Pace NR (1993) Circularly Permuted tRNAs as Specific Photoaffinity Probes of Ribonuclease P RNA Structure. Science 261:762–765PubMedCrossRefGoogle Scholar
  83. 83.
    Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21-­nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494–498PubMedCrossRefGoogle Scholar
  84. 84.
    Chen C, Guo P (1997) Magnesium-induced conformational change of packaging RNA for procapsid recognition and binding during phage phi29 DNA encapsidation. J Virol 71:495–500PubMedGoogle Scholar
  85. 85.
    Wassarman DA (1993) Psoralen crosslinking of small RNAs in vitro. Mol Biol Rep 17:143–151PubMedCrossRefGoogle Scholar
  86. 86.
    Tyc K, Steitz JA (1992) A new interaction between the mouse 5′ external transcribed spacer of pre-rRNA and U3 snRNA detected by psoralen crosslinking. Nucleic Acids Res 20:5375–5382PubMedCrossRefGoogle Scholar
  87. 87.
    Hui CF, Cantor CR (1985) Mapping the location of psoralen crosslinks on RNA by mung bean nuclease sensitivity of RNA-DNA hybrids. Proc Natl Acad Sci USA 82:1381–1385PubMedCrossRefGoogle Scholar
  88. 88.
    Shu D, Huang L, Hoeprich S, Guo P (2003) Construction of phi29 DNA-packaging RNA (pRNA) monomers, dimers and trimers with variable sizes and shapes as potential parts for nano-devices. J Nanosci Nanotechnol 3:295–302PubMedCrossRefGoogle Scholar
  89. 89.
    Chen C, Sheng S, Shao Z, Guo P (2000) A dimer as a building block in assembling RNA: a hexamer that gears bacterial virus phi29 DNA-translocating machinery. J Biol Chem 275:17510–17516PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Peixuan Guo
    • 1
  • Yi Shu
    • 1
  • Daniel Binzel
    • 1
  • Mathieu Cinier
    • 1
    Email author
  1. 1.Nanobiomedical CenterUniversity of CincinnatiCincinnatiUSA

Personalised recommendations